Literature DB >> 18952925

Blood vessel maturation in retinoblastoma tumors: spatial distribution of neovessels and mature vessels and its impact on ocular treatment.

Yolanda Piña1, Hinda Boutrid, Amy Schefler, Sander Dubovy, William Feuer, Maria-Elena Jockovich, Timothy G Murray.   

Abstract

PURPOSE: The purposes of this study were to evaluate the spatial distribution of neovessels versus mature vessels in both human retinoblastoma (RB) and LH(BETA)T(AG) tumors, assess similarities and differences between the animal model and the human RB specimens, and determine whether vessel maturation is associated with risk factors for metastasis.
METHODS: Immunohistochemical analyses were performed on human (n = 10) and LH(BETA)T(AG) (n = 11) enucleation specimens to evaluate the spatial distribution of neovessels and mature vessels. In human RB, vessel maturation was correlated with treatment history and metastatic risk factors.
RESULTS: In human RB, the percentage of neovessels was higher in the periphery of the tumor than in the center (P = 0.021). This finding was mostly attributed to the distribution of large-caliber vessels (i.e., neovessels were higher in the periphery for large [P = 0.050]- and medium [P = 0.032]-caliber vessels; and mature vessels were higher in the center for large-caliber vessels [P = 0.032]). In this small series, vessel maturation did not correlate with risk for metastasis. Similar results were observed in LH(BETA)T(AG) tumors. The percentage of large-caliber neovessels was higher in the periphery than in the center (P = 0.038).
CONCLUSIONS: There is a spatially distributed, heterogeneous vessel population containing neovessels and mature vessels in advanced RB disease. There is a significantly higher concentration of mature, large-caliber vessels in the center of tumors that is similar in human RB and LH(BETA)T(AG) retinal tumors. From these data the authors hypothesize that tumor vessel maturation in RB initiates in central regions of the tumor and radiates toward the periphery.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18952925     DOI: 10.1167/iovs.08-2654

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  13 in total

1.  Retinoblastoma treatment: utilization of the glycolytic inhibitor, 2-deoxy-2-fluoro-D-glucose (2-FG), to target the chemoresistant hypoxic regions in LH(BETA)T(AG) retinal tumors.

Authors:  Yolanda Piña; Christina Decatur; Timothy G Murray; Samuel K Houston; Milena Lopez-Cavalcante; Eleut Hernandez; Magda Celdran; Nikesh Shah; William Feuer; Theodore Lampidis
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-02-27       Impact factor: 4.799

2.  Regional and temporal differences in gene expression of LH(BETA)T(AG) retinoblastoma tumors.

Authors:  Samuel K Houston; Yolanda Pina; Jennifer Clarke; Tulay Koru-Sengul; William K Scott; Lubov Nathanson; Amy C Schefler; Timothy G Murray
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-07-23       Impact factor: 4.799

3.  The TAg-RB murine retinoblastoma cell of origin has immunohistochemical features of differentiated Muller glia with progenitor properties.

Authors:  Sanja Pajovic; Timothy W Corson; Clarellen Spencer; Helen Dimaras; Marija Orlic-Milacic; Mellone N Marchong; Kwong-Him To; Brigitte Thériault; Mark Auspitz; Brenda L Gallie
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-09-29       Impact factor: 4.799

Review 4.  Current update on retinoblastoma.

Authors:  Samuel K Houston; Timothy G Murray; Stacey Quintero Wolfe; Cristina E Fernandes
Journal:  Int Ophthalmol Clin       Date:  2011

5.  Focal, periocular delivery of 2-deoxy-D-glucose as adjuvant to chemotherapy for treatment of advanced retinoblastoma.

Authors:  Yolanda Piña; Samuel K Houston; Timothy G Murray; Hinda Boutrid; Magda Celdran; William Feuer; Wei Shi; Eleut Hernandez; Theodore J Lampidis
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-08-11       Impact factor: 4.799

6.  Residual intraretinal retinoblastoma after chemoreduction failure.

Authors:  Christopher K Hwang; Thomas M Aaberg; Patricia Chevez-Barrios; Elizabeth Verner-Cole; Dan S Gombos; Evelyn Paysse; Murali Chintagumpala; Weiqing Gao; Hans E Grossniklaus
Journal:  Arch Ophthalmol       Date:  2012-02

7.  Irresponsiveness of two retinoblastoma cases to conservative therapy correlates with up- regulation of hERG1 channels and of the VEGF-A pathway.

Authors:  Pina Fortunato; Serena Pillozzi; Angela Tamburini; Liliana Pollazzi; Alessandro Franchi; Agostino La Torre; Annarosa Arcangeli
Journal:  BMC Cancer       Date:  2010-09-22       Impact factor: 4.430

8.  Gelatinase expression in retinoblastoma: modulation of LH(BETA)T(AG) retinal tumor development by anecortave acetate.

Authors:  M Livia Bajenaru; Yolanda Piña; Timothy G Murray; Colleen M Cebulla; William Feuer; Maria-Elena Jockovich; Maria-Encarna Marin Castaño
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-01-27       Impact factor: 4.799

9.  Advanced retinoblastoma treatment: targeting hypoxia by inhibition of the mammalian target of rapamycin (mTOR) in LH(BETA)T(AG) retinal tumors.

Authors:  Y Piña; C Decatur; Tg Murray; Sk Houston; D Gologorsky; M Cavalcante; L Cavalcante; E Hernandez; M Celdran; W Feuer; T Lampidis
Journal:  Clin Ophthalmol       Date:  2011-03-07

10.  Retinoblastoma treatment: impact of the glycolytic inhibitor 2-deoxy-d-glucose on molecular genomics expression in LH(BETA)T(AG) retinal tumors.

Authors:  Yolanda Piña; Samuel K Houston; Timothy G Murray; Tulay Koru-Sengul; Christina Decatur; William K Scott; Lubov Nathanson; Jennifer Clarke; Theodore J Lampidis
Journal:  Clin Ophthalmol       Date:  2012-05-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.